Christie® CounterAct™ products, with patented Care222® technology, emit filtered far-UVC 222nm light that has been shown in the lab to inactivate more than 99% of pathogens and disinfect surfaces—including SARS-CoV-2 (COVID-19), influenza, bacteria, and antibiotic-resistant superbugs.
We know ultraviolet (UV) light can effectively neutralize pathogens, but the typical 254nm wavelength can penetrate human eyes and skin, so it can only be used in unoccupied spaces where no people are present. CounterAct products contain Ushio’s patented Care222 lamps that emit far-UVC 222nm light, a sweet spot on the UV spectrum that’s not only effective against reducing pathogens but may be used around people. And Care222 is the only UVC technology with a proprietary optical filter that prevents longer UVC wavelengths from being emitted. Learn more about how far-UVC light technology works.
CounterAct may be used when people are present
CounterAct products with patented Care222 technology and proprietary filters emit far-UVC 222nm light that cannot penetrate healthy human skin when used in accordance with operational specifications
The patented far-UVC light that Care222 technology emits can reduce surface pathogens—including coronaviruses like the common cold and SARS-CoV-2, influenza, and bacteria
It’s an added layer of defense
CounterAct products with patented Care222 technology emit far-UVC 222nm light that damages the RNA of pathogens like coronaviruses provide an added layer of defense
We can work with you to determine how many CounterAct light modules fixtures you need to provide effective coverage of your indoor space. We offer consulting and installation services through our Professional Services group to help with a deployment strategy to add a layer of defense against pathogens in shared indoor spaces.
Christie CounterAct products with patented Care222 technology are not for use as or for medical devices or for use on humans or animals or to disinfect medical devices.
This product is not intended to diagnose, treat, cure, or prevent any disease.
The pathogen-reducing efficacy of Christie CounterAct products with patented Care222 technology and their use in occupied spaces is dependent on proper installation and operational specifications, in accordance with American Conference of Governmental Industrial Hygienists (ACGIH) guidelines.
Any references to “disinfection’ and “disinfecting” are referring generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition of the term as may be used for other purposes by the U.S. Food and Drug Administration or the U.S. Environmental Protection Agency.
The Care222® standard character mark and stylized logo mark are registered trademarks of Ushio America, Inc.’s patented technology, in the United States, European Union, and United Kingdom.
*Tablet is not included. Android OS only. Recommended tablets for operation: Samsung Galaxy Tab A 8" or 10.1"; VANKYO MatrixPad S8, S10, or S30
Christie CounterAct with Care222 datasheet
Nov 01, 2020 | PDF: 2.7 MB
This document lists the key features and specifications of Christie® CounterAct™.